Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus

Cancer Science

Volumn 99, Issue 2, 2008, Pages 385-390

  Hashimoto, Yuuri ^a   Watanabe, Yuichi ^a   Shirakiya, Yoshiko ^a   Uno, Futoshi ^b   Kagawa, Shunsuke ^b   Kawamura, Hitoshi ^a   Nagai, Katsuyuki ^a   Tanaka, Noriaki ^c   Kumon, Horomi ^b   Urata, Yasuo ^a   Fujiwara, Toshiyoshi ^b  

^a National Institute of Infectious Diseases   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG DETERMINATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LUNG CANCER; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; VIRUS ATTENUATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELL LINE, TUMOR; DNA REPLICATION; DNA, VIRAL; FEMALE; GENOME, VIRAL; HUMANS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; ONCOLYTIC VIROTHERAPY; POLYMERASE CHAIN REACTION; TELOMERASE;

EID: 38949116994     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00665.x     Document Type: Article

References (13)

1. Kohn EC, Lu Y, Wang H et al. Molecular therapeutics: Promise and challenges. Semin Oncol 2004; 31: 39-53.
2. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
3. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-50.
4. Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-9.
5. Hamid O, Varterasian ML, Wadler S et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-504.
6. Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285-92.
7. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
8. Fujiwara T, Tanaka N, Kanazawa S et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689-99.
9. Umeoka T, Kawashima T, Kagawa S et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004; 64: 6259-65.
10. Taki M, Kagawa S, Nishizaki M et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24: 3130-40.
11. Watanabe T, Hioki M, Fujiwara T et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent TRAD in human lung cancer cells. Exp Cell Res 2006; 312: 256-65.
12. Cathomen T, Weitzman MD. A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity. J Virol 2000; 74: 11.407-12.
13. Ouchi M, Kawamura H, Nagai K, Urata Y, Fujiwara T. Antiviral activity of cidofovir against telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301). Mol Ther 2007; 15 (Suppl 1): S173.